시장보고서
상품코드
1192997

세계의 당뇨병 치료제 시장 : 제품별(주사제, 경구 당뇨병 치료제), 기회 분석 및 산업 예측(2020-2030년)

Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 160 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 당뇨병 치료제(Diabetes Therapeutics) 시장은 2020년 1,180억 6,330만 달러에 달했습니다. 2021년부터 2030년까지 10.4%의 CAGR에 달할 전망이며, 2030년 3,179억 1,500만 달러에 달할 것으로 예측됩니다.

당뇨병은 혈당 수치에 이상이 있는 만성 대사 질환입니다. 당뇨병 치료제는 당뇨병 환자가 체내 혈당치를 유지하는 데 사용하는 약물입니다.

세계의 당뇨병 치료제 시장은 당뇨병 유병률 증가, 높은 비만, 앉기 쉬운 라이프 스타일 및 기타 만성 질환으로 인해 가까운 장래에 큰 성장을 기록할 것으로 예상됩니다. 예를 들어, 국제 당뇨병 연합(IDF), 당뇨병 아틀라스에 따르면 2021년 약 5억 3,700만 명의 성인(20-79세)이 당뇨병과 공존하고 있습니다. 또한, 노년 인구 증가는 당뇨병 치료제 시장 성장으로 이어졌습니다. 그러나 항당뇨병 약물로 인한 부작용은 시장 성장을 방해합니다. 반대로 당뇨병 분야의 R&D 활동 자금 증가는 시장 참가자들에게 유익한 기회를 제공할 것으로 기대됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 주요 요약

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • 포터의 5가지 경쟁요인 분석
  • 주요 기업 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19의 영향 분석

제4장 당뇨병 치료약 시장 : 제품별

  • 주요 요약
    • 시장 규모 및 예측
  • 주사제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 경구 당뇨병 치료제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별

제5장 당뇨병 치료약 시장 : 지역별

  • 주요 요약
    • 시장 규모, 예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모, 예측 : 제품별
    • 북미 시장 규모, 예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모, 예측 : 제품별
    • 유럽 시장 규모, 예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽 지역
  • 아시아태평양 지역
    • 주요 동향과 기회
    • 아시아태평양 지역 시장 규모, 예측 : 제품별
    • 아시아태평양 지역 시장 규모, 예측 : 국가별
      • 중국
      • 일본
      • 인도
      • 호주
      • 기타 아시아태평양 지역
  • LAMEA
    • 주요 동향과 기회
    • LAMEA 시장 규모, 예측 : 제품별
    • LAMEA 시장 규모, 예측 : 국가별
      • 브라질
      • 사우디 아라비아
      • 남아프리카
      • 기타 LAMEA 지역

제6장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 발전

제7장 기업 프로필

  • ASTRAZENECA PLC
  • BOEHRINGER INGELHEIM GMBH
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • NOVARTIS AG
  • NOVO NORDISK
  • SANOFI SA
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • johnson and johnson md&d
  • MERCK and CO., INC.
NJH 23.03.20

The global diabetes therapeutics market was valued at $118,063.3 million in 2020, and is projected to reach $317,915 million by 2030, registering a CAGR of 10.4% from 2021 to 2030. Diabetes is a chronic metabolic disorder in which there are abnormalities in blood glucose levels. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.

The global diabetes therapeutics market is expected to register substantial growth in the near future, owing to rise in prevalence of diabetes, high obesity, sedentary lifestyles, and other chronic conditions. For instance, according to International Diabetes Federation (IDF),Diabetes Atlas, in 2021, approximately 537 million adults (20-79 years of age) were living with diabetes.  Furthermore, rise in geriatric population led to an increase in growth of diabetes therapeutics market. However, side effects caused by anti-diabetes medication hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in diabetes sector is expected to offer remunerative opportunities for market players.

The diabetes therapeutics market is segmented into product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag ,Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global diabetes therapeutics market size along with the current trends and future estimations to elucidate the future investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of the region helps to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetes therapeutics market growth.

Key Market Segments

By Product

  • Injectables
  • Oral antidiabetic Drugs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • ASTRAZENECA PLC
    • BOEHRINGER INGELHEIM GMBH
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE PLC
    • NOVARTIS AG
    • NOVO NORDISK
    • SANOFI S.A.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • johnson and johnson md&d
    • MERCK and CO., INC.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETES THERAPEUTICS MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Injectables
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Oral antidiabetic Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: DIABETES THERAPEUTICS MARKET, BY REGION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 North America
    • 5.2.1 Key trends and opportunities
    • 5.2.2 North America Market size and forecast, by Product
    • 5.2.3 North America Market size and forecast, by country
      • 5.2.3.1 U.S.
      • 5.2.3.1.1 Market size and forecast, by Product
      • 5.2.3.2 Canada
      • 5.2.3.2.1 Market size and forecast, by Product
      • 5.2.3.3 Mexico
      • 5.2.3.3.1 Market size and forecast, by Product
  • 5.3 Europe
    • 5.3.1 Key trends and opportunities
    • 5.3.2 Europe Market size and forecast, by Product
    • 5.3.3 Europe Market size and forecast, by country
      • 5.3.3.1 Germany
      • 5.3.3.1.1 Market size and forecast, by Product
      • 5.3.3.2 France
      • 5.3.3.2.1 Market size and forecast, by Product
      • 5.3.3.3 United Kingdom
      • 5.3.3.3.1 Market size and forecast, by Product
      • 5.3.3.4 Italy
      • 5.3.3.4.1 Market size and forecast, by Product
      • 5.3.3.5 Spain
      • 5.3.3.5.1 Market size and forecast, by Product
      • 5.3.3.6 Rest of Europe
      • 5.3.3.6.1 Market size and forecast, by Product
  • 5.4 Asia-Pacific
    • 5.4.1 Key trends and opportunities
    • 5.4.2 Asia-Pacific Market size and forecast, by Product
    • 5.4.3 Asia-Pacific Market size and forecast, by country
      • 5.4.3.1 China
      • 5.4.3.1.1 Market size and forecast, by Product
      • 5.4.3.2 Japan
      • 5.4.3.2.1 Market size and forecast, by Product
      • 5.4.3.3 India
      • 5.4.3.3.1 Market size and forecast, by Product
      • 5.4.3.4 Australia
      • 5.4.3.4.1 Market size and forecast, by Product
      • 5.4.3.5 Rest Of Asia Pacific
      • 5.4.3.5.1 Market size and forecast, by Product
  • 5.5 LAMEA
    • 5.5.1 Key trends and opportunities
    • 5.5.2 LAMEA Market size and forecast, by Product
    • 5.5.3 LAMEA Market size and forecast, by country
      • 5.5.3.1 Brazil
      • 5.5.3.1.1 Market size and forecast, by Product
      • 5.5.3.2 Saudi Arabia
      • 5.5.3.2.1 Market size and forecast, by Product
      • 5.5.3.3 South Africa
      • 5.5.3.3.1 Market size and forecast, by Product
      • 5.5.3.4 Rest of LAMEA
      • 5.5.3.4.1 Market size and forecast, by Product

CHAPTER 6: COMPANY LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product Mapping of Top 10 Player
  • 6.4. Competitive Dashboard
  • 6.5. Competitive Heatmap
  • 6.6. Key developments

CHAPTER 7: COMPANY PROFILES

  • 7.1 ASTRAZENECA PLC
    • 7.1.1 Company overview
    • 7.1.2 Company snapshot
    • 7.1.3 Operating business segments
    • 7.1.4 Product portfolio
    • 7.1.5 Business performance
    • 7.1.6 Key strategic moves and developments
  • 7.2 BOEHRINGER INGELHEIM GMBH
    • 7.2.1 Company overview
    • 7.2.2 Company snapshot
    • 7.2.3 Operating business segments
    • 7.2.4 Product portfolio
    • 7.2.5 Business performance
    • 7.2.6 Key strategic moves and developments
  • 7.3 ELI LILLY AND COMPANY
    • 7.3.1 Company overview
    • 7.3.2 Company snapshot
    • 7.3.3 Operating business segments
    • 7.3.4 Product portfolio
    • 7.3.5 Business performance
    • 7.3.6 Key strategic moves and developments
  • 7.4 GLAXOSMITHKLINE PLC
    • 7.4.1 Company overview
    • 7.4.2 Company snapshot
    • 7.4.3 Operating business segments
    • 7.4.4 Product portfolio
    • 7.4.5 Business performance
    • 7.4.6 Key strategic moves and developments
  • 7.5 NOVARTIS AG
    • 7.5.1 Company overview
    • 7.5.2 Company snapshot
    • 7.5.3 Operating business segments
    • 7.5.4 Product portfolio
    • 7.5.5 Business performance
    • 7.5.6 Key strategic moves and developments
  • 7.6 NOVO NORDISK
    • 7.6.1 Company overview
    • 7.6.2 Company snapshot
    • 7.6.3 Operating business segments
    • 7.6.4 Product portfolio
    • 7.6.5 Business performance
    • 7.6.6 Key strategic moves and developments
  • 7.7 SANOFI S.A.
    • 7.7.1 Company overview
    • 7.7.2 Company snapshot
    • 7.7.3 Operating business segments
    • 7.7.4 Product portfolio
    • 7.7.5 Business performance
    • 7.7.6 Key strategic moves and developments
  • 7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 7.8.1 Company overview
    • 7.8.2 Company snapshot
    • 7.8.3 Operating business segments
    • 7.8.4 Product portfolio
    • 7.8.5 Business performance
    • 7.8.6 Key strategic moves and developments
  • 7.9 johnson and johnson md&d
    • 7.9.1 Company overview
    • 7.9.2 Company snapshot
    • 7.9.3 Operating business segments
    • 7.9.4 Product portfolio
    • 7.9.5 Business performance
    • 7.9.6 Key strategic moves and developments
  • 7.10 MERCK and CO., INC.
    • 7.10.1 Company overview
    • 7.10.2 Company snapshot
    • 7.10.3 Operating business segments
    • 7.10.4 Product portfolio
    • 7.10.5 Business performance
    • 7.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제